Cryoport Is Selected By Morphotek to Manage Cold Chain Logistics

Shipments of proprietary technologies support the development of
innovative new therapies for cancer, inflammation and infectious disease

IRVINE, Calif. & EXTON, Pa.–(BUSINESS WIRE)–Cryoport,
Inc
. (NASDAQ:CYRX),
(“Company”), the world’s leading cryogenic logistics company, and
Morphotek® announced that Cryoport is providing end-to-end
cold chain logistics support for shipments of Morphotek’s research and
development materials.

Morphotek, a subsidiary of Eisai Inc., a global health care
pharmaceutical company, is a life science company that develops novel
classes of biological-based products to treat cancer, inflammation and
infectious diseases. Since its founding in 2000, Morphotek has made
extraordinary progress in discovering and developing monoclonal
antibodies (mAbs) being studied in diseases using its proprietary
technology platforms:

  • Human MORPHODOMA® technology employs an ex vivo
    immunization process in combination with morphogenics to generate
    fully human antibodies targeted against disease-associated antigens.
    The resultant antibodies are fully human with high-affinity and target
    specificity.
  • Libradoma™ technology generates libraries of hybridomas that can be
    rapidly screened to identify fully human monoclonal antibodies to
    known antigens and novel targets for the diagnosis and treatment of
    diseases in humans. This platform is being widely pursued internally
    to feed Morphotek’s future therapeutic antibody pipeline.

Global Supply Chain Management Director of Morphotek, Mr. Myron Waskiw,
stated, “By selecting Cryoport for our cold chain logistics, we are
partnering with the most experienced cryogenic solutions provider.
Cryoport understands the critical nature of our shipments, has the
advanced capabilities to track conditions and location of our products
in transit around the clock, and, importantly, has the intervention
capability to mitigate any logistics risks. Cryoport’s solutions and
capabilities are critical to the successful development of our
therapeutic candidates.”

Mark Sawicki, PhD, Chief Commercial Officer of Cryoport, said, “Cryoport
is thrilled to have been selected by Morphotek to manage the cold chain
logistics supporting research for its biological-based programs to treat
cancer, inflammation and infectious diseases. This relationship further
solidifies our position as the leading provider of complete cold chain
solutions for innovative therapeutics.”

Cryoport is currently supporting 52 clinical trials for advanced
therapies and regenerative medicines, including 10 in Phase III, for
biopharmaceutical companies around the world.

About Cryoport, Inc.
Cryoport is the premier provider of
cryogenic logistics solutions to the life sciences industry through its
purpose-built proprietary packaging, information technology and
specialized cold chain logistics expertise. The company provides
leading-edge logistics solutions for biologic materials, such as
immunotherapies, stem cells, CAR-T cells and reproductive cells for
clients worldwide. Leading global companies, such as FedEx, UPS and DHL,
have each separately selected Cryoport as the preferred cryogenic
logistics provider for time- and temperature-sensitive biological
material. Cryoport actively supports points-of-care, CROs, central
laboratories, pharmaceutical companies, contract manufacturers and
university researchers. For more information, visit www.cryoport.com.

To download Cryoport’s investor relations app, which offers access to
SEC documents, press releases, videos, audiocasts and more, please click
to download from your iPhone+and+iPad&index=4&md5=7120ec91249f7ae4069f7de32017c67b” rel=”nofollow”>iPhone
and iPad or Android+mobile+device&index=5&md5=a41e50718c7d9b16a8d84bc93d969195″ rel=”nofollow”>Android
mobile device.

About Morphotek
Morphotek®, Inc., a subsidiary of
Eisai Inc., is a biopharmaceutical company specializing in the
development of protein and antibody products through the use of a novel
and proprietary gene evolution technology. The technology has been
successfully applied to a broad variety of cell lines and organisms to
yield genetically diverse offspring that are suitable for pharmaceutical
product development in the areas of antibody therapeutics, protein
therapeutics, product manufacturing, drug target discovery, and improved
output traits for commercial applications. The company is currently
focusing its platform on the development and manufacturing of
therapeutic antibodies for the treatment of cancer, inflammation and
infectious disease. For more information, please visit www.morphotek.com.

About Eisai Inc.
At Eisai Inc., human health care is our
goal. We give our first thoughts to patients and their families, and
helping to increase the benefits health care provides. As the U.S.
pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a
passionate commitment to patient care that is the driving force behind
our efforts to help address unmet medical needs. We are a fully
integrated pharmaceutical business with discovery, clinical,
manufacturing and marketing capabilities. Our key areas of commercial
focus include oncology and specialty care (Alzheimer’s disease, epilepsy
and metabolic disorders). To learn more about Eisai Inc., please visit
us at www.eisai.com.

Eisai Inc. has affiliates that are part of a global product creation
organization that includes R&D facilities in Massachusetts, New Jersey,
North Carolina and Pennsylvania, as well as a global demand chain
organization that includes manufacturing facilities in Maryland and
North Carolina. Eisai’s global areas of R&D focus include neuroscience;
oncology; metabolic disorders; vascular, inflammatory and immunological
reaction; and antibody-based programs.

Morphotek®, MORPHODOMA®, Libradoma™ are trademarks
of Eisai Co. Ltd.

Cryoport Forward Looking Statements
Statements in this
news release which are not purely historical, including statements
regarding Cryoport, Inc.’s intentions, hopes, beliefs, expectations,
representations, projections, plans or predictions of the future are
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. It is important to note that the
company’s actual results could differ materially from those in any such
forward-looking statements. Factors that could cause actual results to
differ materially include, but are not limited to, risks and
uncertainties associated with the effect of changing economic
conditions, trends in the products markets, variations in the company’s
cash flow, market acceptance risks, and technical development risks. The
company’s business could be affected by a number of other factors,
including the risk factors listed from time to time in the company’s SEC
reports including, but not limited to, the annual report on Form 10-K
for the year ended March 31, 2015. The company cautions investors not to
place undue reliance on the forward-looking statements contained in this
press release. Cryoport, Inc. disclaims any obligation, and does not
undertake to update or revise any forward-looking statements in this
press release.

Contacts

For Cryoport
SCORR Marketing
Lea Studer,
308-237-5567
lea@scorrmarketing.com
or
Cryoport
Investor Contacts:
Todd Fromer, +1 212-682-6300
tfromer@kcsa.com
or
Garth
Russell, +1 212-682-6300
grussell@kcsa.com
or
Morphotek
Contact:
Myron Waskiw, 610-423-6100
Director, Global Supply
Chain Management